Vertex Pharmaceuticals Incorporated, a biotechnology company, develops medicines for serious diseases. The company focuses on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs. It markets ORKAMBI (lumacaftor in combination with ivacaftor) to treat patients with CF 12 years of age and older who are homozygous for the F508del mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene; KALYDECO (ivacaftor) for the treatment of patients with CF who have specific mutations in their CFTR gene, including the G551D mutation; and SYMDEKO (tezacaftor in combination with ivacaftor) to treat patients with CF 12 years of age and older who are F508del homozygous or who have 1 mutation that is responsive to tezacaftor/ivacaftor. The company also develops VX-659 and VX-445, which are CFTR corrector compounds in Phase II clinical trial; VX-150 that is in Phase II clinical trial to treat pain; VX-128, which is in Phase I clinical trial for the treatment of pain; CTX001, an investigational gene editing treatment that is in Phase I/II trial for the treatment of beta-thalassemia and sickle cell disease; pimodivir (JNJ-63623872), which is in a Phase III clinical development program to treat influenza; and VX-210 to treat acute spinal cord injury. It sells its products primarily to specialty pharmacy providers in North America, as well as government-owned and supported customers internationally. The company has collaborations with Cystic Fibrosis Foundation Therapeutics Incorporated; CRISPR Therapeutics AG; Moderna Therapeutics, Inc.; BioAxone Biosciences, Inc.; Parion Sciences, Inc.; Merck KGaA; Janssen Pharmaceuticals, Inc; and Q-State Biosciences, Inc. The company was founded in 1989 and is headquartered in Boston, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone617-341-6100
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$2.49 billion
Profitability
Miscellaneous
Employees2,300
OptionableOptionable
Vertex Pharmaceuticals (NASDAQ:VRTX) Frequently Asked Questions
What is Vertex Pharmaceuticals' stock symbol?
Vertex Pharmaceuticals trades on the NASDAQ under the ticker symbol "VRTX."
How will Vertex Pharmaceuticals' stock buyback program work?
Vertex Pharmaceuticals announced that its board has authorized a stock buyback plan on Thursday, February 1st 2018, which permits the company to buyback $500,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization permits the company to reacquire shares of its stock through open market purchases. Shares buyback plans are generally an indication that the company's leadership believes its stock is undervalued.
How were Vertex Pharmaceuticals' earnings last quarter?
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) released its quarterly earnings results on Wednesday, October, 24th. The pharmaceutical company reported $1.09 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.02 by $0.07. The pharmaceutical company had revenue of $784.54 million for the quarter, compared to the consensus estimate of $782.95 million. Vertex Pharmaceuticals had a return on equity of 22.92% and a net margin of 22.87%. During the same period in the previous year, the company posted $0.53 EPS. View Vertex Pharmaceuticals' Earnings History.
When is Vertex Pharmaceuticals' next earnings date?
What price target have analysts set for VRTX?
22 Wall Street analysts have issued 1 year price targets for Vertex Pharmaceuticals' stock. Their predictions range from $165.71 to $220.00. On average, they anticipate Vertex Pharmaceuticals' share price to reach $201.0855 in the next twelve months. This suggests a possible upside of 4.0% from the stock's current price. View Analyst Price Targets for Vertex Pharmaceuticals.
What is the consensus analysts' recommendation for Vertex Pharmaceuticals?
22 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vertex Pharmaceuticals in the last year. There are currently 4 hold ratings and 18 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Vertex Pharmaceuticals.
What are Wall Street analysts saying about Vertex Pharmaceuticals stock?
Here are some recent quotes from research analysts about Vertex Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Although we are positive on Vertex’s decision to focus on the CF franchise, we remain concerned about the company’s dependence on just this franchise for growth. While the company does have other pipeline candidates targeting other therapeutic areas, it is too early to get excited about them. Competitive pressure is rising in the CF market with many other companies developing triple combo CF medicines. Vertex has faced some challenges with respect to commercialization of Orkambi in ex-U.S. markets due to re-imbursement hurdles. However, Vertex’s non-CF pipeline, though early stage, looks interesting." (12/31/2018)
- 2. Cantor Fitzgerald analysts commented, ". Reiterate overweight and $217 price target. This morning, Vertex announced that CFO Tom Graney has resigned effective immediately. He joined 2017, so his tenure was relatively short." (12/17/2018)
Has Vertex Pharmaceuticals been receiving favorable news coverage?
News headlines about VRTX stock have trended very positive this week, InfoTrie reports. The research firm identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Vertex Pharmaceuticals earned a media sentiment score of 3.2 on InfoTrie's scale. They also assigned headlines about the pharmaceutical company a news buzz of 4.0 out of 10, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.
Who are some of Vertex Pharmaceuticals' key competitors?
Some companies that are related to Vertex Pharmaceuticals include AbbVie (ABBV), Abbott Laboratories (ABT), Eli Lilly And Co (LLY), Novo Nordisk A/S (NVO), Sanofi (SNY), GlaxoSmithKline (GSK), AstraZeneca (AZN), Bristol-Myers Squibb (BMY), Bayer (BAYRY), Celgene (CELG), Shire (SHPG), Allergan (AGN), Regeneron Pharmaceuticals (REGN), Zoetis (ZTS) and ASTELLAS PHARMA/ADR (ALPMY).
Who are Vertex Pharmaceuticals' key executives?
Vertex Pharmaceuticals' management team includes the folowing people:
- Mr. Jeffrey Marc Leiden, Chairman, CEO & Pres (Age 62)
- Mr. Thomas Graney, CFO & Sr. VP (Age 53)
- Mr. Ian F. Smith, Exec. VP & COO (Age 52)
- Dr. David M. Altshuler, Chief Scientific Officer & Exec. VP of Global Research (Age 53)
- Mr. Michael J. Parini, Exec. VP and Chief Legal & Admin. Officer (Age 43)
Who are Vertex Pharmaceuticals' major shareholders?
Vertex Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Atalanta Sosnoff Capital LLC (0.12%), Retirement Systems of Alabama (0.06%), Gateway Investment Advisers LLC (0.06%), Cullinan Associates Inc. (0.05%), Peregrine Capital Management LLC (0.04%) and Nisa Investment Advisors LLC (0.04%). Company insiders that own Vertex Pharmaceuticals stock include Amit Sachdev, David Altshuler, Ian F Smith, Jeffrey Chodakewitz, Jeffrey M Leiden, Margaret G Mcglynn, Michael Parini, Paul M Silva, Reshma Kewalramani, Sangeeta N Bhatia, Stuart A Arbuckle and Thomas Graney. View Institutional Ownership Trends for Vertex Pharmaceuticals.
Which major investors are selling Vertex Pharmaceuticals stock?
VRTX stock was sold by a variety of institutional investors in the last quarter, including Factory Mutual Insurance Co., Gulf International Bank UK Ltd, Oakbrook Investments LLC, Nisa Investment Advisors LLC, DNB Asset Management AS, Boston Advisors LLC, Louisiana State Employees Retirement System and Atalanta Sosnoff Capital LLC. Company insiders that have sold Vertex Pharmaceuticals company stock in the last year include Amit Sachdev, David Altshuler, Ian F Smith, Jeffrey Chodakewitz, Jeffrey M Leiden, Margaret G Mcglynn, Michael Parini, Paul M Silva, Reshma Kewalramani, Sangeeta N Bhatia, Stuart A Arbuckle and Thomas Graney. View Insider Buying and Selling for Vertex Pharmaceuticals.
Which major investors are buying Vertex Pharmaceuticals stock?
VRTX stock was bought by a variety of institutional investors in the last quarter, including Gateway Investment Advisers LLC, Peregrine Capital Management LLC, Meeder Asset Management Inc., Cullinan Associates Inc., First Citizens Bank & Trust Co., Broadleaf Partners LLC, QUANTRES ASSET MANAGEMENT Ltd and Eastern Bank. View Insider Buying and Selling for Vertex Pharmaceuticals.
How do I buy shares of Vertex Pharmaceuticals?
Shares of VRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Vertex Pharmaceuticals' stock price today?
One share of VRTX stock can currently be purchased for approximately $193.34.
How big of a company is Vertex Pharmaceuticals?
Vertex Pharmaceuticals has a market capitalization of $49.76 billion and generates $2.49 billion in revenue each year. The pharmaceutical company earns $263.48 million in net income (profit) each year or $0.80 on an earnings per share basis. Vertex Pharmaceuticals employs 2,300 workers across the globe.
What is Vertex Pharmaceuticals' official website?
How can I contact Vertex Pharmaceuticals?
Vertex Pharmaceuticals' mailing address is 50 NORTHERN AVENUE, BOSTON MA, 02210. The pharmaceutical company can be reached via phone at 617-341-6100 or via email at [email protected]
MarketBeat Community Rating for Vertex Pharmaceuticals (NASDAQ VRTX)
MarketBeat's community ratings are surveys of what our community members think about Vertex Pharmaceuticals and other stocks. Vote "Outperform" if you believe VRTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VRTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
